abstract |
The present invention relates to a novel natural killer cell line and use thereof and, more particularly, to a novel natural killer cell line which is positive to CD2, CD11a, CD25, CD45, CD54, CD56, and HLA-DR; and negative to CD1a, CD3, CD4, CD8, CD14, CD16, CD20, CD23, CD34, TCRαβ, and TCRγδ, and use thereof such as a pharmaceutical composition comprising the same for treatment of cancer. |